Efficacy of intravitreal bevacizumab (AvastinTM) for short-term treatment of diabetic macular edema by Nagasawa, Toshihiko et al.
INTRODUCTION
Diabetic retinopathy (DR) is a major cause of
visual loss in patients with diabetes mellitus. Dia-
betic macular edema (DME), which can occur at
any stage of DR, is characterised by increased vas-
cular permeability and the deposition of hard exu-
dates at the central retina. Diabetic macular edema
is now the principal cause of vision loss in people
with diabetes (1).
Bevacizumab (AvastinTM, Genentech Inc. San
Francisco, California, USA) is a full length human-
ized antibody that binds to all subtypes of vascular
endothelial growth factor (VEGF) and has been ap-
proved by the US Food and Drug Administration for
the treatment of metastatic colorectal cancer (2). Re-
cent reports have suggested that bevacizumab may
be useful for the treatment of choroidal neovascu-
larization (CNV), diabetic macular edema, DR and
macular edema associated with retinal venous occlu-
sive diseases (3-5).
The purpose of this study was to report the effi-
cacy of intravitreal injections of bevacizumab by
measuring visual acuity (VA) and foveal retinal
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thickness (RT) after intravitreal injection of bevaci-
zumab for DME.
METHODS
We retrospectively reviewed 20 eyes of 19 con-
secutive Japanese patients (12 males, 7 females)
with DME treated with intravitreally administered
bevacizumab. The patients were followed for four
weeks at Tokushima University Hospital. The Ethi-
cal Committee of the University of Tokushima ap-
proved the off-label use of bevacizumab. The deci-
sion to treat with intravitreally administered bevaci-
zumab was made by the patient after a complete dis-
cussion on its risks, benefits and alternative treat-
ments. If the patient decided to proceed with bevaci-
zumab therapy, they signed a consent form before
administration.
The eye was prepared with a topical anesthetic
and a drop of antibiotic before the injection. The eye-
lid margin was prepared with a povidone/iodine so-
lution. A wire speculum was placed followed by sev-
eral drops of diluted povidone/iodine solution to the
conjunctiva at the injection site. An injection of 1.25
mg of bevacizumab (0.05 ml of bevacizumab at a
concentration of 25 mg/ml) was administered using
a 30 gauge needle from the pars plana.
Patients were examined at baseline, at one week,
two weeks, and four weeks. We recorded the BCVA
measured with a Japanese standard decimal VA
chart and calculated the mean BCVA using the loga-
rithm of the minimum angle of resolution (logMAR)
scale, intraocular pressure (IOP), and fluorescein an-
giography (FA). Analysis of retinal anatomic features
was performed using an optical coherence tomogra-
phy (OCT, Stratus III OCT ; Carl Zeiss, Dublin,
California, USA). The RT at the fovea of the 1-mm
central retina was determined using six low-reso-
lution diagonally oriented fast macula scans.
Statistical analysis was performed using the Stu-
dent’s t -test to compare the VA, IOP and the cen-
tral RT at one, two, and four weeks from baseline.
RESULTS
Twenty eyes of 19 patients (12 males, 7 females)
with DME were studied. The ages of the patients
ranged from 44 to 76 years with a mean of 59.7
8.0 years. All patients had type II diabetes. There
was no history of any other ocular disease except
for refractive errors or cataracts. All patients had
panretinal photocoagulation. Three patients had sub-
Tenon’s capsule injection of 20 mg triamcinolone
acetonide (TA). Nine patients had cataract surgery
with intraocular lens implantation, and nine pa-
tients had vitrectomy. The glycosylated hemoglobin
(HbA1c) averaged 7.11.1 before starting the study
(Table 1).
The BCVA at one week improved by two lines or
more in six eyes (30%) (Figure 1) and the BCVA at
Table 1 Clinical characteristics of 19 patients (20 eyes) with
diabetic macula edema at baseline.
Gender, no
Male 12
Female 7
Age(years), MeanSD 59.78.0
Glycosylated hemoglobin (HbA1C, %), MeanSD 7.11.1
Panretinal photocoagulation 20
Macula focal/grid laser treatment 0
Prior sub tenon triamcinolone injection 3
Prior pars plana vitrectomy 9
Lens status, no
Phakic 11
Pseudophakia 9
Baseline retinal thickness, MeanSD (μm) 411170
Figure 1 Scattergram of BCVA (1 week) and baseline.
Changes in the best-corrected visual acuity (BCVA) at one week
after treatment. Six eyes (30%) improved by two lines or more,
one eye (5%) decreased by two lines or more.
There is no significant improvement between the mean BCVA
and baseline (P0.05, paired t - test).
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four weeks improved in nine eyes (45%) (Figure 2).
No significant improvement in the mean BCVA from
baseline was observed at one week (P0.05), or
four weeks (P0.05).
Mean RT was 411170 μm at baseline, 349102
μm at one week, 365149 μm at two weeks, and
380159 μm at four weeks (Figure 3). The central
RT significantly decreased from baseline at one
week (P0.05). However, no significant decrease
was recognized at two weeks (P0.05), and four
weeks (P0.05). At the four weeks follow-up visit,
FA showed resolution of leakage in some eyes.
During the follow-up of the patients in this study,
no complications such as inflammation, increased
IOP (Figure 4), severe vision loss, endophthalmitis,
or systemic events were observed.
DISCUSSION
DME has been characterized by inflammation, in-
cluding intravitreous induction of proinflammatory
cytokines (6), intraretinal expression of proinflam-
matory caspases (7) and mediators. Many clinical
investigators have found that an intravitreal injection
of TA may reduce macular edema. However, the use
of intravitreal TA may lead to complications such
as increased IOP, progression of cataract and en-
dophthalmitis (8).
Bevacizumab is an anti-VEGF agent that is ap-
proved for the treatment of disseminated colorectal
cancer but is not licensed for intraocular use. How-
ever, bevacizumab appears to show a similar efficacy
for the treatment of DME and proliferative DR (9).
VEGF has been shown to be an endothelial cell-
specific mitogen and an angiogenic inducer. It is also
a vascular permeability factor ; it has been demon-
strated to increase the permeability of retinal ves-
sels by increasing the phosphorylation of tight junc-
tion proteins (10). It was found that the concentra-
tion of VEGF in the vitreous increased and corre-
lated with the severity of macular edema in patients
with DME (11), therefore anti-VEGF therapy is
expected to show a dramatic reduction of DME.
Bevacizumab has attracted interest because of its
low cost ; however systemic safety is not approved
Figure 2 Scattergram of BCVA (4 weeks) and baseline.
Changes in the best. -corrected visual acuity (BCVA) at four
weeks after treatment. Nine eyes (45%) improved by two lines or
more, 3 eyes (15%) decreased by two lines or more.
There is no significant improvement between the mean BCVA
and baseline (P0.05, paired t - test).
Figure 3 Changes in central retinal thickness throughout the
study.
The central RT significantly decreased from baseline at one weeks
(P0.05). However, it did not significantly decrease at two weeks
(P0.05), and four weeks (P0.05).
Figure 4 Changes of intra ocular pressure throughout the
study.
No significant increase of IOP is seen.
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(12, 13).
We conformed to the widely used concentration
of the drug (1.25 mg bevacizumab) in this study.
Anti-VEGF therapy of the intravitreally administered
bevacizumab showed a marked reduction of macu-
lar edema soon after the injection at one week. How-
ever, recurrence of macular edema occurred within
four weeks. A retinal penetration study revealed the
absence of bevacizumab four weeks after the injec-
tion (14), which may suggest the limited effect of
bevacizumab on suppression of VEGF activity.
Mean retinal thickness was reduced at one week
after the injection (P0.05). However, no significant
improvement in the mean BCVA. It is possible that
visual acuity may not improve with the same time
course as thickness of the macula. It depends on
macular function improvement and it may have
timelag (15).
Maia, et al. reported that a combination therapy
of intravitreal triamcinolone and laser photocoagu-
lation decreased DME (16). Recently, a combination
therapy with intravitreal bevacizumab and photody-
namic therapy (PDT) for CNV in patients with AMD
has been reported to improve VA and anatomic
changes and reduce retreatment rates (17). There-
fore, we think that the combination of laser photo-
coagulation with intravitreal bevacizumab may im-
prove BCVA and decrease RT more than laser pho-
tocoagulation alone or intravitreal bevacizumab alone
for the treatment of moderate DME.
In summary, the therapy of intravitreal bevacizu-
mab alone for DME is effective in the short-term,
however it is not effective in the long-term.
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